Search results for "Rini"

showing 10 items of 746 documents

Anxiolytic effects of muscarinic acetylcholine receptors agonist oxotremorine in chronically stressed rats and related changes in BDNF and FGF2 level…

2017

Rationale: In depressive disorders, one of the mechanisms proposed for antidepressant drugs is the enhancement of synaptic plasticity in the hippocampus and cerebral cortex. Previously, we showed that the muscarinic acetylcholine receptor (mAChR) agonist oxotremorine (Oxo) increases neuronal plasticity in hippocampal neurons via FGFR1 transactivation. Objectives: Here, we aimed to explore (a) whether Oxo exerts anxiolytic effect in the rat model of anxiety-depression-like behavior induced by chronic restraint stress (CRS), and (b) if the anxiolytic effect of Oxo is associated with the modulation of neurotrophic factors, brain-derived neurotrophic factor (BDNF) and fibroblast growth factor-2…

0301 basic medicineMalemedicine.medical_specialtyElevated plus mazemedicine.drug_classBehavioral testPrefrontal CortexHippocampal formationAnxietyMuscarinic AgonistsAnxiolyticHippocampus03 medical and health sciences0302 clinical medicineInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineMuscarinic acetylcholine receptor M4AnimalsElevated plus maze testRats WistarPrefrontal cortexmAChRChronic restraint streForced swimming testPharmacologyNeuronsChemistryBrain-Derived Neurotrophic FactorOxotremorineCerebral cortexRats030104 developmental biologymedicine.anatomical_structureEndocrinologyAnti-Anxiety AgentsCerebral cortexFibroblast Growth Factor 2Anxiety; Behavioral test; Cerebral cortex; Chronic restraint stress; Elevated plus maze test; Forced swimming test; mAChR; Neurotrophins; Novelty suppressed feeding test; PharmacologyNeurotrophinNovelty suppressed feeding testNeuroscience030217 neurology & neurosurgeryStress Psychologicalmedicine.drugPsychopharmacology
researchProduct

Non-neuronal acetylcholine involved in reproduction in mammals and honeybees.

2017

Bacteria and archaea synthesize acetylcholine (ACh). Thus, it can be postulated that ACh was created by nature roughly three billion years ago. Therefore, the wide expression of ACh in nature (i.e., in bacteria, archaea, unicellular organisms, plants, fungi, non-vertebrates and vertebrates and in the abundance of non-neuronal cells of mammals) is not surprising. The term non-neuronal ACh and non-neuronal cholinergic system have been introduced to describe the auto- and paracrine, that is, local regulatory actions of ACh in cells not innervated by neuronal cholinergic fibers and to communicate among themselves. In this way non-neuronal ACh binds to the nicotinic or muscarinic receptors expre…

0301 basic medicineMammalsInsecticidesNicotineCholinergic FibersBiologyBiochemistryEmbryonic stem cellReceptors MuscarinicAcetylcholineCell biology03 medical and health sciencesCellular and Molecular NeuroscienceParacrine signalling030104 developmental biologyNicotinic agonistCell MovementMuscarinic acetylcholine receptormedicineOviductAnimalsHumansAcetylcholineFunction (biology)medicine.drugJournal of neurochemistry
researchProduct

Regulation of GC box activity by 8-oxoguanine

2021

The oxidation-induced DNA modification 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) was recently implicated in the activation and repression of gene transcription. We aimed at a systematic characterisation of the impacts of 8-oxodG on the activity of a GC box placed upstream from the RNA polymerase II core promoter. With the help of reporters carrying single synthetic 8-oxodG residues at four conserved G:C base pairs (underlined) within the 5′-TGGGCGGAGC-3′ GC box sequence, we identified two modes of interference of 8-oxodG with the promoter activity. Firstly, 8-oxodG in the purine-rich (but not in the pyrimidine-rich) strand caused direct impairment of transcriptional activation. In addit…

0301 basic medicineMedicine (General)GuanineDNA RepairQH301-705.5Clinical BiochemistryCAAT box8-OxoguanineRNA polymerase IIBiochemistryDNA GlycosylasesAP endonuclease03 medical and health sciencesR5-9200302 clinical medicineGene expressionDNA-(Apurinic or Apyrimidinic Site) LyaseAP siteBiology (General)AP lesionbiologyChemistryOrganic ChemistryPromoterBase excision repairMolecular biologyGC boxBase excision repair (BER)030104 developmental biologyDNA glycosylasebiology.protein8-Oxoguanine DNA Glycosylase (OGG1)030217 neurology & neurosurgeryResearch PaperDNA DamageRedox Biology
researchProduct

Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist/β2-Adrenoceptor Agonist Molecule with Long-Lasting Effect…

2019

AZD8871 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic obstructive pulmonary disease. This study describes the pharmacological profile of AZD8871 in in vitro and in vivo assays. AZD8871 is potent at the human M3 receptor (pIC50 in binding assays: 9.5) and shows kinetic selectivity for the M3 (half-life: 4.97 hours) over the M2 receptor (half-life: 0.46 hour). It is selective for the β2-adrenoceptor over the β1 and β3 subtypes (3- and 6-fold, respectively) and shows dual antimuscarinic and β2-adrenoceptor functional activity in isolated guinea pig tissue (pIC50 in electrically stimulated trachea: 8.6; pEC50 in spontaneous tone isolated trachea: 8.8, r…

0301 basic medicinePharmacologyAgonistChemistrymedicine.drug_classAntagonistMuscarinic antagonistMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2PropranololPharmacology03 medical and health sciences030104 developmental biology0302 clinical medicineIn vivoMuscarinic acetylcholine receptormedicineMolecular Medicine030217 neurology & neurosurgerymedicine.drugJournal of Pharmacology and Experimental Therapeutics
researchProduct

Analysis of cross-resistance to Vip3 proteins in eight insect colonies, from four insect species, selected for resistance to Bacillus thuringiensis i…

2018

Abstract Bacillus thuringiensis Vip3 proteins are synthesized and secreted during the vegetative growth phase. They are activated by gut proteases, recognize and bind to midgut receptors, form pores and lyse cells. We tested the susceptibility to Vip3Aa and Vip3Ca of Cry1A-, Cry2A-, Dipel- and Vip3-resistant insect colonies from different species to determine whether resistance to other insecticidal proteins confers cross-resistance to Vip3 proteins. As expected, the colonies resistant to Cry1A proteins, Dipel (Helicoverpa armigera, Trichoplusia ni, Ostrinia furnacalis and Plodia interpunctella) or Cry2Ab (H. armigera and T. ni) were not cross-resistant to Vip3 proteins. In contrast, H. arm…

0301 basic medicineProteasesInsectabiologymedia_common.quotation_subjectfungi030106 microbiologyBacillus thuringiensisMidgutInsectHelicoverpa armigerabiology.organism_classificationMicrobiologyInsecticide Resistance03 medical and health sciencesBacterial ProteinsBacillus thuringiensisTrichoplusiaAnimalsPest Control BiologicalEcology Evolution Behavior and SystematicsCross-resistancemedia_commonOstrinia furnacalisJournal of Invertebrate Pathology
researchProduct

Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β 2 -adrenoceptor agonist (MA…

2017

LAS190792 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic respiratory diseases. This study investigated the pharmacological profile of LAS190792 in comparison to batefenterol, tiotropium, indacaterol and olodaterol. LAS190792 is potent at the human M3 receptor (pIC50: 8.8 in binding assays). It is selective for the β2-adrenoceptor over the β1-and β3-adrenoceptor, and shows a functional potency in a similar range to batefenterol and LABA compounds (pEC50 in spontaneous tone isolated trachea: 9.6). The relaxant potency of LAS190792 in electrically stimulated tissue is similar to batefenterol, with an antimuscarinic activity in presence of propranolol sl…

0301 basic medicinePulmonary and Respiratory MedicineAgonistmedicine.drug_classBiochemistry (medical)OlodaterolAntagonistMuscarinic acetylcholine receptor M3Muscarinic antagonistPropranololPharmacology03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicine030228 respiratory systemchemistryCompetitive antagonistMuscarinic acetylcholine receptormedicinePharmacology (medical)medicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

2020

Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 1…

0301 basic medicineSYMPTOMSSmart phoneAllergyEscala visual analógicaINNOVATION[SDV]Life Sciences [q-bio]Medical and Health SciencesCorrelationvisual analogue scale0302 clinical medicineQuality of lifeVisual analogue scaleQUALITY-OF-LIFEMàscaresImmunology and AllergyscoreNoseRinitisRhinitisPRODUCTIVITY COSTSasthma; MASK; rhinitis; score; visual analogue scaleScoreExplained variationResponse VariabilityMobile ApplicationsALLERGIC RHINITISrhinitimedicine.anatomical_structureTRIALSRinite1107 Immunology[SDV.IMM]Life Sciences [q-bio]/ImmunologySmartphonemedicine.medical_specialtyMASKVisual analogue scaleMASK study groupImmunologyMACVIA-ARIA03 medical and health sciencesAllergicrhinitismedicineHumansvisual analogue scale.TECHNOLOGYIMMUNOTHERAPYAsmaAsthmabusiness.industryasthma; MASK; rhinitis; score; visual analogue scale; Humans; Smartphone; Asthma; Mobile Applications; Rhinitis; Rhinitis Allergicasthmamedicine.diseaseRhinitis AllergicAsthmaRHINOCONJUNCTIVITIS030104 developmental biology030228 respiratory system3121 General medicine internal medicine and other clinical medicinePhysical therapyClinical Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Regulatory identification of BPA as an endocrine disruptor : Context and methodology

2018

International audience; BPA is one of the most investigated substances for its endocrine disruptor (ED) properties and it is at the same time in the center of many ED-related controversies, the analysis on how BPA fits to the regulatory identification as an ED is a challenge in terms of methodology. It is also a great opportunity to test the regulatory framework with a uniquely data-rich substance and learn valuable lessons for future cases. From this extensive database, it was considered important to engage in a detailed analysis so as to provide specific and strong evidences of ED while reflecting accurately the complexity of the response as well the multiplicity of adverse effects. An ap…

0301 basic medicineendocrine systemBrain developmentpertubateur endocrinienEndocrine disruptionContext (language use)Computational biologyMESH: Social Control Formal010501 environmental sciencesBiologyEndocrine Disruptors01 natural sciencesBiochemistryMammary gland developmentbisphenol A;endocrine disruption;ED;SVHC;substance of very high concern;REACh03 medical and health sciencesEndocrinologyBisphenol AMESH: PhenolsPhenolsSubstance of very high concernMESH: Benzhydryl CompoundsFood and Nutritionbisphénol aAnimalsHumansBenzhydryl CompoundsMolecular BiologyComputingMilieux_MISCELLANEOUSSVHC0105 earth and related environmental sciencesEndocrinology and metabolismurogenital systemsubstance toxiqueED3. Good healthSocial Control FormalMESH: Endocrine Disruptors030104 developmental biologyEndocrine disruptor[SDV.TOX]Life Sciences [q-bio]/ToxicologyAlimentation et NutritionEndocrinologie et métabolismeREACHIdentification (biology)
researchProduct

Protective Effect of Pogostone on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis via Inhibition of T Helper Cell

2017

Inflammatory bowel disease (IBD) is a chronic immune-related disease mainly caused by the disequilibrium of T helper (Th) cell paradigm? Pogostone (PO) is one of the major chemical constituents of Pogostemon cablin (Blanco) Benth. The present study aims to investigate the potential benefit of PO against IBD in a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis model. PO treatment by enema significantly brought down the disease activity index (DAI) of the TNBS-challenged rats, which was manifested by the ameliorated inflammatory features including ulceration, adhesion, and edema. Hematoxylin-eosin (HE) staining and immunohistochemistry analysis showed that PO effectivel…

0301 basic medicineexperimental colitisCellPharmacologyInflammatory bowel diseaseProinflammatory cytokine03 medical and health scienceschemistry.chemical_compound246-Trinitrobenzenesulfonic acidEdemamedicinePharmacology (medical)T helper cellOriginal ResearchPharmacologybiologyCell growthbusiness.industrylcsh:RM1-950pogostoneT helper cellmedicine.diseaseTNBSanti-inflammationdigestive system diseaseslcsh:Therapeutics. Pharmacology030104 developmental biologymedicine.anatomical_structurechemistryMyeloperoxidaseImmunologybiology.proteinmedicine.symptombusinessFrontiers in Pharmacology
researchProduct

Multifaceted Mechanisms of WY-14643 to Stabilize the Blood-Brain Barrier in a Model of Traumatic Brain Injury

2017

The blood-brain barrier (BBB) is damaged during ischemic insults such as traumatic brain injury or stroke. This contributes to vasogenic edema formation and deteriorate disease outcomes. Enormous efforts are pursued to understand underlying mechanisms of ischemic insults and develop novel therapeutic strategies. In the present study the effects of PPARα agonist WY-14643 were investigated to prevent BBB breakdown and reduce edema formation. WY-14643 inhibited barrier damage in a mouse BBB in vitro model of traumatic brain injury based on oxygen/glucose deprivation in a concentration dependent manner. This was linked to changes of the localization of tight junction proteins. Furthermore, WY-1…

0301 basic medicinepirinixic acidTraumatic brain injuryp38 mitogen-activated protein kinasesIschemiaischemiaPharmacologyBlood–brain barrierPPARαlcsh:RC321-57103 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineDownregulation and upregulationmedicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryMolecular BiologyOriginal ResearchTight junctionbusiness.industryKinasetraumatic brain injuryblood-brain barriermedicine.diseasestroke030104 developmental biologymedicine.anatomical_structureKnockout mousebusinessNeuroscience030217 neurology & neurosurgeryNeuroscienceFrontiers in Molecular Neuroscience
researchProduct